



Press release

Cantargia AB
556791-6019
1 March 2021

Cantargia provides business updates at investor conferences during March 2021

Cantargia AB ("Cantargia") will participate at several international investor conferences during March to present the company, the drug candidates CAN04 and CAN10 and future plans. For details, see below.

Event: H.C. Wainwright Global Life Sciences Conference

Date and time: March 9-10, 2021

Location: Virtual

About: <https://hcwevents.com/globalconference/>

Event: Carnegie Nordic Virtual Healthcare Seminar

Date and time: March 10, 2021, 09:00 - 09:30

Event: Oppenheimer 31st Annual Healthcare Conference

Date and time: March 16, 2021, 15:00 - 15:30

Location: Virtual

About: <https://www.oppenheimer.com/events/2021/31st-annual-healthcare-conference.aspx>

For further information, please contact

Göran Forsberg, CEO

Telephone: +46 (0)46-275 62 60

E-mail: <mailto:goran.forsberg@cantargia.com>

This information was submitted for publication, at 12.30 CET on 1 March 2021.

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04, is being studied clinically as combination therapy with chemotherapy or immune therapy with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy show a higher response rate than would be expected from chemotherapy alone. Cantargia's second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

About CAN04

The antibody CAN04 binds strongly to the target IL1RAP and functions both through ADCC as well as blocking IL-1 α and IL-1 β signaling. Thereby, CAN04 can counteract the contribution of the IL-1 system to the immune suppressive tumor microenvironment and development of resistance to chemotherapy. CAN04 is investigated in two clinical trials. In the first phase I/IIa-study, CANFOUR, first line combination therapy is investigated using two different standard chemotherapies in 31 patients with NSCLC (gemcitabine/cisplatin) and 31 patients with PDAC (gemcitabine/nab-paclitaxel), as well as monotherapy in late stage patients (<https://clinicaltrials.gov/ct2/show/NCT03267316>). Phase I monotherapy data from 22 patients were presented at ASCO 2019 and showed good safety with infusion related reaction being the most common side effect. In addition, the biomarkers IL6 and CRP decreased during treatment. Positive interim data from the combination

arms was presented during H2 2020 and showed a higher response rate than expected from chemotherapy alone. A phase I study investigating CAN04 in combination with an immune checkpoint inhibitor started H2 2020 (<https://clinicaltrials.gov/ct2/show/NCT04452214>). Additional clinical combination studies are planned to start during 2021.